Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC

Amgen to Acquire Gene-Hunting Firm

By BiotechDaily International staff writers
Posted on 07 Jan 2013
Biotechnology giant Amgen (Thousand Oaks, CA, USA) is set to acquire deCODE Genetics (Reykjavik, Iceland), a global leader in analyzing and understanding the human genome.

The acquisition is intended to bolster Amgen’s drug discovery efforts by developing drugs based on human genetic discoveries, which have had a better track record than drugs developed by animal models that often do not work. deCODE Genetics, founded in 1996, has discovered genetic risk factors for dozens of diseases, ranging from cardiovascular disease to schizophrenia, cancer, and numerous other diseases. In 2012 alone, the company published studies on a rare mutation that protects people from getting Alzheimer’s disease and a study suggesting that older men are more likely to father children with autism.

In January 2010 most of deCODE genetics assets were purchased by Saga Investments (Akureyri, Iceland) an investment company whose owners include Polaris Venture Partners and ARCH Venture Partners, with the intention of continuing most services and retaining the management team. The all-cash transaction values deCODE Genetics at USD 415 million (subject to customary closing adjustments), and does not require regulatory approval. The acquisition is expected to close before the end of 2012.

“deCODE Genetics has built a world-class capability in the study of the genetics of human disease; this capability will enhance our efforts to identify and validate human disease targets,” said Robert A. Bradway, president and CEO at Amgen. “This fits perfectly with our objective to pursue rapid development of relevant molecules that reach the right disease targets while avoiding investments in programs based on less well-validated targets.”

“One of the ways to truly realize the full value of human genetics, is to make our research synergistic with drug development efforts where target discovery, validation, and prioritization efforts can be accelerated,” said Kari Stefansson, MD, founder and CEO of deCODE Genetics. “We believe Amgen's focus and ability to incorporate our genetic research into their research and development efforts will translate our discoveries into meaningful therapies for patients.”

In the late 1990s deCODE collected medical records and genealogical and genetic data of the entire population of Iceland (which numbered 270,000 at the time), creating the Icelandic Health Sector Database (HSD). The HSD became very controversial, and prompted both national and international criticism for its approach to the concepts of privacy and consent. A legal judgment from the Icelandic Supreme Court in November 2003 effectively killed off the HSD project.

Related Links:
Amgen
deCODE Genetics


Channels

Genomics/Proteomics

view channel
Image: Transmission electron micrograph of norovirus particles in feces (Photo courtesy of Wikimedia Commons).

Norovirus Interacts with Gut Bacteria to Establish a Persistent Infection That Can Be Blocked by Interferon Lambda

A team of molecular microbiologists and virologists has found that norovirus requires an intimate interaction with certain gut bacteria to establish a persistent infection, and that the infective process... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Therapeutics

view channel
Image: Cancer cells infected with tumor-targeted oncolytic virus (red). Green indicates alpha-tubulin, a cell skeleton protein. Blue is DNA in the cancer cell nuclei (Photo courtesy of Dr. Rathi Gangeswaran, Bart’s Cancer Institute).

Innovative “Viro-Immunotherapy” Designed to Kill Breast Cancer Cells

A leading scientist has devised a new treatment that employs viruses to kill breast cancer cells. The research could lead to a promising “viro-immunotherapy” for patients with triple-negative breast cancer,... Read more

Lab Technologies

view channel
Image: MIT researchers have designed a microfluidic device that allows them to precisely trap pairs of cells (one red, one green) and observe how they interact over time (Photo courtesy of Burak Dura, MIT).

New Device Designed to See Communication between Immune Cells

The immune system is a complicated network of many different cells working together to defend against invaders. Effectively combating an infection depends on the interactions between these cells.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.